Type2 Diabetes Clinical Trial
Official title:
"Non-invasive Measurement of Hepatic Substrate Flux Rates in Patients With Diabetes Mellitus Type 2"
Verified date | August 2023 |
Source | German Diabetes Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
WP 1: Working hypothesis: The gluconeogenic flux rates from pyruvate (lactate, alanine) and glycerol are higher in patients with T2D compared to the healthy control group. WP2: Working Hypothesis: The gluconeogenic flux rates of lactate and glycerol are reduced in patients with T2D by acute inhibition of the redox shuttle.
Status | Enrolling by invitation |
Enrollment | 12 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - T2D + metformin therapy - healthy volunteers Exclusion Criteria: - no metformin therapy |
Country | Name | City | State |
---|---|---|---|
Germany | German Diabetes Center | Duesseldorf | NRW |
Lead Sponsor | Collaborator |
---|---|
German Diabetes Center | Yale University |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The gluconeogenic flux rates from pyruvate (lactate, alanine) and glycerol are higher in patients with T2D compared to the healthy control group. | The present study tests the hypothesis that the GDP redox-shuttle is overactive and responsible for excessive GNG in human T2D what could be enhanced by adipocines secreted from inflammed adipose tissue in obese.
It is a randomized controlled trial investigating liver energy metabolism in patients with T2D with and without inhibition of redox shuttle in patients with T2D and compared to a healthy control group (age- and BMI corrected). Patients and healthy controls are included prospectively. The combination of PINTA method and MRS determines the flux rates of pyruvate (lactate and alanine) and glycerol as well as gluconeogenesis and glycogenolysis. In addition, acute cellular changes after acute inhibition of the redox shuttle are investigated. |
2 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03239366 -
A Study to Evaluate the Effect of BioK+ 50B® on Glycemic Control in a Type 2 Diabetes Population
|
Phase 2 | |
Completed |
NCT04597229 -
Efficacy of Multigrain Supplementation in Type II Diabetes Mellitus
|
N/A | |
Completed |
NCT03623139 -
Effects of Basic Carbohydrate Counting Versus Standard Outpatient Nutritional Education in Type 2 Diabetes
|
N/A | |
Active, not recruiting |
NCT04599920 -
Effects of Replacing Red Meat With Legumes on Biomarkers of Chronic Diseases in Healthy Men (Leg4Life)
|
N/A | |
Active, not recruiting |
NCT03422471 -
Hypoglycemia and Autonomic Nervous System Function- B2
|
N/A | |
Completed |
NCT04382521 -
A Text Message Intervention to Promote Health Behaviors in Cardiac Risk Conditions
|
N/A | |
Recruiting |
NCT04564391 -
Whey or Casein - Liver Fat Reduction and Metabolic Improvement by Fast vs. Slow Proteins
|
N/A | |
Recruiting |
NCT03458715 -
The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix Insulin
|
Phase 4 | |
Terminated |
NCT03278236 -
Does Time Restricted Feeding Improve Glycaemic Control in Overweight Men?
|
N/A | |
Completed |
NCT02974504 -
Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)
|
Phase 4 | |
Completed |
NCT05053828 -
Type 2 Diabetes With Antiplatelet Drugs
|
||
Not yet recruiting |
NCT03659383 -
The Exploration of Optimal Treatment Scheme in Patients With Type 2 Diabetes Inadequately Controlled With Glargine
|
Phase 4 | |
Completed |
NCT03542240 -
Effects of Curcumin Supplementation on Gut Barrier Function in Patients With Metabolic Syndrome
|
N/A | |
Completed |
NCT03657537 -
Effects of Ketone Bodies on Cognition in Type 2 Diabetes
|
Phase 1 | |
Completed |
NCT03979768 -
Risk Assessment of Type 2 Diabetes in Pharmacies
|
N/A | |
Completed |
NCT03614039 -
Effect of Probiotic and Smectite Gel on NAFLD
|
N/A | |
Active, not recruiting |
NCT04994288 -
A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients
|
Phase 2/Phase 3 | |
Completed |
NCT03290768 -
Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics - (Protocol 3)
|
N/A | |
Completed |
NCT03643783 -
Impact of Plasma Soluble Prorenin Receptor in Obese and Type 2 Diabetic Patients
|
||
Active, not recruiting |
NCT04451837 -
Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology
|
Phase 2 |